

### Online Supplementary Table S9

**Table S9. Summary of anti-drug antibodies (ADA) data up to the end of the safety period, by treatment and visit (Safety analysis set)**

<b>Visit</b>	<b>GP2013 N=133 n/N' (%)</b>	<b>RTX-US N=92 n/N' (%)</b>	<b>RTX-EU N=87 n/N' (%)</b>
<b>ADAs by visit</b>			
V3/Randomization	0/130 (0.0)	3/87 (3.4)	2/87 (2.3)
V8/Week 4	0/122 (0.0)	0/77 (0.0)	2/79 (2.5)
V11/Week 16	5/121 (4.1)	0/79 (0.0)	3/80 (3.8)
V12/Week 24	12/120 (10.0)	7/79 (8.9)	6/79 (7.6)
V13/Week 38	9/104 (4.8)	0/71 (0.0)	12/73 (16.4)
V14/Week 52	7/98 (5.1)	0/68 (0.0)	6/65 (9.2)
V101/Safety F/U	2/39 (2.6)	6/82 (7.3)	2/27 (7.4)
<b>Overall post-baseline</b>	<b>GP2013</b>	<b>RTX</b>	
Positive	21/127 (16.5)	25/166 (15.1)	
Transient	13/127 (10.2)	16/166 (9.6)	
Neutralizing ADA	5/127 (3.9)	1/166 (0.6%)	